Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Cash from Financing Activities (2016 - 2022)

Historic Cash from Financing Activities for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q4 2022 value amounting to $6.6 million.

  • Avadel Pharmaceuticals' Cash from Financing Activities changed N/A to $6.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $14.5 million, marking a year-over-year increase of 542965.78%. This contributed to the annual value of $16.0 million for FY2024, which is 8819.97% down from last year.
  • Avadel Pharmaceuticals' Cash from Financing Activities amounted to $6.6 million in Q4 2022.
  • In the past 5 years, Avadel Pharmaceuticals' Cash from Financing Activities registered a high of $122.9 million during Q1 2018, and its lowest value of -$9.8 million during Q2 2018.
  • Over the past 5 years, Avadel Pharmaceuticals' median Cash from Financing Activities value was $103000.0 (recorded in 2019), while the average stood at $17.1 million.
  • In the last 5 years, Avadel Pharmaceuticals' Cash from Financing Activities plummeted by 9992.52% in 2019 and then skyrocketed by 31714324.32% in 2020.
  • Avadel Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$76000.0 in 2018, then surged by 46.05% to -$41000.0 in 2019, then surged by 546.34% to $183000.0 in 2020, then crashed by 37.7% to $114000.0 in 2021, then skyrocketed by 5708.77% to $6.6 million in 2022.
  • Its last three reported values are $6.6 million in Q4 2022, $10.7 million for Q3 2022, and -$4.8 million during Q2 2022.